Mexico City /
Although gradually measures to prevent more infections of COVID-19s vaccination campaigns all over the world continue, this with the aim of protect as many people as possibleAndS.including the minors.
According to a report released by Chilean Institute of Public Health (ISP)the CoronaVac vaccine for COVID-19 manufactured by Sinovac Biotech Ltd. ex safe for children from the 3 years.
In the 4th ESAVI statistical report it was evaluated 6 million 946,000 593 doses of SARS-CoV-2 vaccines which have been applied to children and adolescents since From 1 March 2021 to 26 February 2022of which over 70% came from Sinovac, a COVID-19 vaccine available for children 3 and 5 years in Chile.
“In total, they reported 868 adverse events reported associated with vaccination (ESAVI) at a rate of 12.50 notifications for every 100,000 doses administered. For CoronaVac, the rate was 10.67. Of the total ESAVI, they have been classified 107 equally serious cases, at a rate of 1.54 severe ESAVI notifications per 100,000 doses administered. Similarly, it was noted a lower rate of 1.31 for the SINOVAC COVID-19 vaccine“, was detailed in a statement.
It should be noted that the latest results of the Phase II pediatric clinical trials in China They also suggest that a third dose of CoronaVac shows good protection against the Omicron variant in children aged 3 to 5 years.
A total of 14 countries and regions Worldwide approved the COVID-19 vaccine CoronaVac to be used in minors and adolescents, so that more than 280 million children have been inoculated.
